These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 18511826)
1. Health economics in technology development: is it worth it? Lee D J Nucl Med; 2008 Jun; 49(6):48N-50N. PubMed ID: 18511826 [No Abstract] [Full Text] [Related]
2. Health economics in public health. Ammerman AS; Farrelly MA; Cavallo DN; Ickes SB; Hoerger TJ Am J Prev Med; 2009 Mar; 36(3):273-5. PubMed ID: 19215853 [TBL] [Abstract][Full Text] [Related]
5. White biotech and the financial crisis. Rabinovich M Biotechnol J; 2009 Aug; 4(8):1117-23. PubMed ID: 19685465 [No Abstract] [Full Text] [Related]
6. Health economics--what the nephrologist should know. Palmer AJ Nephrol Dial Transplant; 2005 Jun; 20(6):1038-41. PubMed ID: 15840678 [No Abstract] [Full Text] [Related]
7. Perspective: A tale of 'cautious pessimism': Biotechnology, recession and the 'new economy'. Kewell B; Webster A Biotechnol J; 2009 Aug; 4(8):1106-8. PubMed ID: 19685467 [No Abstract] [Full Text] [Related]
8. Paying for the biomedical future. Weber DO Health Forum J; 1999; 42(4):35. PubMed ID: 10539020 [No Abstract] [Full Text] [Related]
9. Health economics and nursing management. Newbold D J Nurs Manag; 2005 Sep; 13(5):373-6. PubMed ID: 16108774 [No Abstract] [Full Text] [Related]
10. Clinical trials and health economics--a marriage of convenience or a marriage made in heaven? Bakhai A; Greenberg D J Med Econ; 2008; 11(3):541-6. PubMed ID: 19450103 [No Abstract] [Full Text] [Related]
11. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods. Sculpher M; Claxton K Health Econ; 2010 Oct; 19(10):1132-6. PubMed ID: 20662107 [No Abstract] [Full Text] [Related]
12. Drivers of health care costs: technology vs social, legal, and behavioral factors. Thrall JH J Am Coll Radiol; 2009 Jun; 6(6):387-8. PubMed ID: 19467479 [No Abstract] [Full Text] [Related]
13. Forming an international biotechnology spinout: is it worth it? Christoffersen RE Nat Biotechnol; 1999 Feb; 17 Suppl():BE20-1. PubMed ID: 10052319 [No Abstract] [Full Text] [Related]
14. Time for a common standard for cost-effectiveness in Europe? Jönsson B Eur J Health Econ; 2006 Dec; 7(4):223-4. PubMed ID: 17077979 [No Abstract] [Full Text] [Related]
15. IQWiG methods--a response to two critiques. Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P Health Econ; 2010 Oct; 19(10):1137-8. PubMed ID: 20842681 [No Abstract] [Full Text] [Related]
16. Future costs in economic evaluation. A comment on Lee. Feenstra TL; van Baal PH; Gandjour A; Brouwer WB J Health Econ; 2008 Dec; 27(6):1645-9; discussion 1650-1. PubMed ID: 18823670 [TBL] [Abstract][Full Text] [Related]
17. Some essential clarifications: IQWiG comments on two critiques of the efficiency frontier approach. Dintsios CM; Gerber A Health Econ; 2010 Oct; 19(10):1139-41. PubMed ID: 20842682 [No Abstract] [Full Text] [Related]
18. We have a shortage of specialists. Yamamoto LG Am J Emerg Med; 2005 Nov; 23(7):895-6. PubMed ID: 16291448 [No Abstract] [Full Text] [Related]
19. [Economic analysis of therapeutic actions--fundamental concepts and examples of application]. Shinbo T Nihon Naika Gakkai Zasshi; 2000 Jun; 89(6):1206-11. PubMed ID: 10892199 [No Abstract] [Full Text] [Related]
20. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]